Humanigen Takes Aim At IL-6 Inhibitors With CRS Drug Lenzilumab

Company Targets COVID-19, CAR-T, GvHD Markets

 
• By Alaric DeArment
  
3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration
Humanigen is developing lenzilumab for cytokine release syndrome due to causes like CAR-T therapy and COVID-19. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip